nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.06.2012 | Clinical Investigation

Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma

verfasst von: Dirk Schnapauff, Timm Denecke, Christian Grieser, Federico Colletini, Daniel Seehofer, Marianne Sinn, Jan Banzer, Enrique Lopez-Hänninen, Bernd Hamm, Peter Wust, Bernhard Gebauer

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was designed to investigate the clinical outcome of patients with irresectable, intrahepatic cholangiocarcinoma (IHC) treated with computed tomography (CT)-guided HDR-brachytherapy (CT-HDRBT) for local tumor ablation.

Method

Fifteen consecutive patients with histologically proven cholangiocarcinoma were selected for this retrospective study. Patients were treated by high-dose-rate internal brachytherapy (HDRBT) using an Iridium-192 source in afterloading technique through CT-guided percutaneous placed catheters. A total of 27 brachytherapy treatments were performed in these patients between 2006 and 2009. Median tumor enclosing target dose was 20 Gy, and mean target volume of the radiated tumors was 131 (± 90) ml (range, 10–257 ml). Follow-up consisted of clinical visits and magnetic resonance imaging of the liver every third month. Statistical evaluation included survival analysis using the Kaplan–Meier method.

Results

After a median follow-up of 18 (range, 1–27) months after local ablation, 6 of the 15 patients are still alive; 4 of them did not get further chemotherapy and are regarded as disease-free. The reached median local tumor control was 10 months; median local tumor control, including repetitive local ablation, was 11 months. Median survival after local ablation was 14 months and after primary diagnosis 21 months.

Conclusion

In view of current clinical data on the clinical outcome of cholangiocarcinoma, locally ablative treatment with CT-HDRBT represents a promising and safe technique for patients who are not eligible for tumor resection.

Olnes MJ, Erlich R (2004) A review and update on cholangiocarcinoma. Oncology 66:167–179PubMedCrossRef

Shaib Y, El-Serag HB (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115–125PubMedCrossRef

Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24:189–199PubMedCrossRef

Jarnagin WR, Fong Y, DeMatteo RP et al. (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517; discussion 517–519

Shimada K, Sano T, Sakamoto Y et al (2007) Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 31:2016–2022PubMedCrossRef

Jonas S, Thelen A, Benckert C et al (2009) Extended liver resection for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 249:303–309PubMedCrossRef

Lieser MJ, Barry MK, Rowland C et al (1998) Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg 5:41–47PubMedCrossRef

Hammill CW, Wong LL (2008) Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 207:594–603PubMedCrossRef

Chu KM, Lai EC, Al-Hadeedi S et al. (1997) Intrahepatic cholangiocarcinoma. World J Surg 21:301–305; discussion 305–306

10.

Endo I, Gonen M, Yopp AC et al (2008) Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248:84–96PubMedCrossRef

11.

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281PubMedCrossRef

12.

Guglielmi A, Ruzzenente A, Valdegamberi A et al (2008) Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 12:192–198PubMedCrossRef

13.

Carrafiello G, Lagana D, Cotta E et al (2010) Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc Intervent Radiol 33:835–839PubMedCrossRef

14.

Vogl TJ, Straub R, Eichler K et al (2002) Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 225:367–377PubMedCrossRef

15.

Mantero S, Longo I, Fiore GB et al (2003) Hyperthermia in the treatment of cholangiocarcinoma: development and testing of an endobiliary microwave device. Cardiovasc Intervent Radiol 26:379–385PubMedCrossRef

16.

Bi AH, Zeng ZC, Ji Y et al (2010) Impact factors for microinvasion in intrahepatic cholangiocarcinoma: a possible system for defining clinical target volume. Int J Radiat Oncol Biol Phys 78:1427–1436PubMedCrossRef

17.

Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479–485PubMedCrossRef

18.

Mohnike K, Wieners G, Schwartz F et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–179PubMedCrossRef

19.

Ricke J, Wust P, Wieners G et al (2004) Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 15:1279–1286PubMedCrossRef

20.

Ishii H, Furuse J, Nagase M et al (2004) Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: results without stenting. Hepatogastroenterology 51:954–957PubMed

21.

Golfieri R, Giampalma E, Renzulli M et al (2006) Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo 20:757–760PubMed

22.

Takamura A, Saito H, Kamada T et al (2003) Intraluminal low-dose-rate 192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 57:1357–1365PubMedCrossRef

23.

Allison RR, Zervos E, Sibata CH (2009) Cholangiocarcinoma: an emerging indication for photodynamic therapy. Photodiagnosis Photodyn Ther 6:84–92PubMedCrossRef

24.

Shin HS, Seong J, Kim WC et al (2003) Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 57:105–112PubMedCrossRef

25.

Qian XJ, Zhai RY, Dai DK et al (2006) Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J Gastroenterol 12:331–335PubMed

26.

Cantore M, Mambrini A, Fiorentini G et al (2005) Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103:1402–1407PubMedCrossRef

27.

Hong K, Geschwind JF (2010) Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol 37:110–117PubMedCrossRef

28.

Chiou YY, Hwang JI, Chou YH et al (2005) Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J Med Sci 21:304–309PubMedCrossRef

29.

Yamamoto M, Takasaki K, Otsubo T et al (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8:154–157PubMedCrossRef

30.

Ibrahim SM, Mulcahy MF, Lewandowski RJ et al (2008) Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113:2119–2128PubMedCrossRef

31.

Herber S, Otto G, Schneider J et al (2007) Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 30:1156–1165PubMedCrossRef

32.

Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 31:883–888PubMedCrossRef

33.

Poggi G, Amatu A, Montagna B et al (2009) OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32:1187–1192PubMedCrossRef

34.

Shinohara ET, Guo M, Mitra N et al (2010) Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 78:722–728PubMedCrossRef

Titel: Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma
verfasst von: Dirk Schnapauff
Timm Denecke
Christian Grieser
Federico Colletini
Daniel Seehofer
Marianne Sinn
Jan Banzer
Enrique Lopez-Hänninen
Bernd Hamm
Peter Wust
Bernhard Gebauer
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 3/2012
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-011-0249-0

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Computed Tomography-Guided Interstitial HDR Brachytherapy (CT-HDRBT) of the Liver in Patients with Irresectable Intrahepatic Cholangiocarcinoma